Duragesic® D-TRANS®, a new matrix delivery system for fentanyl: Progress in a new technology;Durogesic® D-TRANS®, nouveau système de délivrance du fentanyl par matrice: Les progrès d'une nouvelle technologie

Douleurs

Volumn 6, Issue 2 I, 2005, Pages 105-108

  Gupta, Suneel K ^a  

^a ALZA CORPORATION   (United States)

Author keywords

Bio equivalence; Fentanyl; Pain; Pharmacokinetics; Skin adherence; Skin tolerance; Transdermal delivery

Indexed keywords

FENTANYL; MORPHINE; MU OPIATE RECEPTOR AGONIST; OPIATE;

ADULT; AGED; CHRONIC PAIN; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; HUMAN; PATIENT CARE; PATIENT COMPLIANCE; PHOTOTOXICITY; REVIEW; SKIN SENSITIZATION; STEADY STATE;

EID: 19944417965     PISSN: 16245687     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1624-5687(05)80242-2     Document Type: Article

References (9)

1. Dossier d'AMM 2004 - A pharmacokinetic study evaluating the bioequivalency of Transdermal D-Trans® fentanyl 100μg/h matrix system to DurogesicTM (fentanyl transdermal patch) 100μg/h after single application in healthy subjects. Protocol C-2002-046.
2. Dossier d'AMM 2004 - A pharmacokinetic study evaluating the bioequivalence of transdermal D-Trans® fentanyl 100μg/h matrix system with DurogesicTM (fentanyl transdermal patch) 100μg/h after repeated application in healthy subjects. Protocol C-2002-049.
3. rd World Congress World Institute of Pain 2004.
4. rd World Congress World Institute of Pain 2004.
5. rd World Congress World Institute of Pain 2004.
6. Thompson JP, Bower S, Liddle AM, Rowbotham DJ. Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. Br J Anaesth 1998;81:152-4.
7. Clinical Research Report Durogesic® D-TRANS®, data on file.
8. rd World Congress World Institute of Pain 2004.
9. rd World Congress World Institute of Pain 2004.